Your session is about to expire
← Back to Search
Virus Therapy
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Phase 1 & 2
Waitlist Available
Research Sponsored by Ziopharm
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new cancer treatment, Ad-RTS-hIL-12 given with veledimex, to see if it is safe and tolerable in children. This treatment is designed to improve the body's natural response to disease by enhancing the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.
Eligible Conditions
- Brain Tumor
- Diffuse Intrinsic Pontine Glioma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Arm 2 - OpenExperimental Treatment2 Interventions
Intratumoral Ad-RTS-hIL-12 stereotactic injection and oral veledimex (activator ligand) in pediatric patients with DIPG.
Group II: Arm 1 - ClosedExperimental Treatment2 Interventions
Intratumoral Ad-RTS-hIL-12 freehand injection after tumor resection and oral veledimex (activator ligand) in pediatric patients with brain tumors.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ad-RTS-hIL-12
2015
Completed Phase 2
~150
Find a Location
Who is running the clinical trial?
ZiopharmLead Sponsor
35 Previous Clinical Trials
3,997 Total Patients Enrolled
Alaunos TherapeuticsLead Sponsor
40 Previous Clinical Trials
4,221 Total Patients Enrolled
Jill BuckStudy DirectorZIOPHARM Oncology, Inc.